References
Collins R, Peto F, MacMahon S: Blood pressure, stroke, and coronary heart disease, part 2: short term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet 1990, 335:827–838.
Staessen JA, Wang J: Blood-pressure lowering for the secondary prevention of stroke. Lancet 2001, 358:1026–1027.
The Heart Outcomes Prevention Evaluation Study Investigators:Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000, 342:145–154.
Hansson L, Lindholm LH, Niskanen L, et al., and the CAPPPStudy Group: Effect of angiotensin converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999, 353:611–616.
Messerli FH, Grossman E, Goldbourt U: Are β-blockers efficacious as first-line therapy for hypertension in the elderly? JAMA 1998, 279:1903–1907.
Rights and permissions
About this article
Cite this article
Schiffrin, E.L. Progress in secondary prevention of stroke with PROGRESS. Current Science Inc 4, 39–40 (2002). https://doi.org/10.1007/s11906-002-0051-0
Issue Date:
DOI: https://doi.org/10.1007/s11906-002-0051-0